metabolic research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Nuclear physics === Some energetic states of an atomic nucleus (having distinct spatial mass, charge, spin, isospin distributions) are much longer-lived than others (nuclear isomers of the same isotope), e.g. technetium-99m. The isotope tantalum-180m, although being a metastable excited state, is long-lived enough that it has never been observed to decay, with a half-life calculated to be least 2.9×1017 (290 quadrillion) years, over 21 million times the current age of the universe.
Yale University entered into its own licensing agreement with a private company, leading Fenn to file a lawsuit against the school in 1996. Yale countersued, requesting damages and reassignment of the patent. The two parties did not reach an out of court settlement, despite repeated attempts at mediation. In 2005, U.S. District Judge Christopher Droney ruled against Fenn, awarding Yale $545,000 in royalties and $500,000 in legal fees. Judge Droney was critical of Fenn, saying "Dr. Fenn only obtained the patent through fraud, civil theft, and breach of fiduciary duty." Evidence presented in the case indicated that Fenn had served on panels at Yale University that reviewed the institution's policy on intellectual property. A spokesperson for Yale said, "We are pleased by the result in this case and, in particular, by the court's vindication of the Yale patent policy." The ruling, and Yale's response produced a mixed reaction from some of Fenn's colleagues and former students, who wrote a letter to the Yale Daily News stating, "'Vindicating the Yale patent policy' is a poor excuse for treating a Nobel Laureate with a 68-year association with and dedicated service to the University, in such a contemptible manner."
One of the largest organizations working to avoiding food distribution crises on the global stage in the Food and Agriculture Organization (FAO). The FAO is a branch of the United Nations, and actively works to improve food distribution in countries that need support
Sources: en.wikipedia.org
=== Firestone recall and legal mandates === The Firestone recall in the late 1990s (which was linked to more than 100 deaths from rollovers following tire tread-separation), pushed the United States Congress to legislate the TREAD Act. The Act mandated the use of a suitable TPMS technology in all light motor vehicles (under 10,000 lb (4,500 kg)), to help alert drivers of under-inflation events. This act affects all U.S. light motor vehicles sold after September 1, 2007. Phase-in started in October 2005 at 20%, and reached 100% for models produced after September 2007. In the United States, as of 2008 and the European Union, as of November 1, 2012, all new passenger car models (M1) released must be equipped with a TPMS. From November 1, 2014, all new passenger cars sold in the European Union must be equipped with a TPMS. For N1 vehicles (trucks up to 3.5 tonnes), TPMS are not mandatory, but if a TPMS is fitted, it must comply with the regulation. On July 13, 2010, the South Korean Ministry of Land, Transport and Maritime Affairs announced a pending partial-revision to the Korea Motor Vehicle Safety Standards (KMVSS), specifying that "TPMS shall be installed to passenger vehicles and vehicles of GVW 3.5 tons or less, ... [effective] on January 1, 2013 for new models and on June 30, 2014 for existing models". Japan is expected to adopt European Union legislation approximately one year after European Union implementation. Further countries to make TPMS mandatory include Russia, Indonesia, the Philippines, Israel, Malaysia and Turkey.
Leaders reaffirmed support for Ukraine's sovereignty and territorial integrity, agreed to increase deliveries of air defence systems, interceptors and long-range capabilities, and said they would strengthen sanctions on Russia, including in the oil and gas sectors. The statement also supported Ukraine's energy resilience through the following winter and said G7 members were ready to consider extending licences to increase Ukrainian military production. The statement on the Middle East welcomed the announcement of a deal between the United States and Iran and said G7 members were ready to contribute to its implementation. It also supported efforts to resume maritime traffic through the Strait of Hormuz and called for diversified energy supply routes and higher energy stocks. It also supported efforts to disarm Hezbollah in Lebanon, accelerate humanitarian and reconstruction efforts in Gaza, and end violence in the West Bank.
==== Metabolism ==== In the liver, hydrocodone is transformed into several metabolites, including norhydrocodone, hydromorphone, 6α-hydrocodol (dihydrocodeine), and 6β-hydrocodol. 6α- and 6β-hydromorphol are also formed, and the metabolites of hydrocodone are conjugated (via glucuronidation). Hydrocodone has a terminal half-life that averages 3.8 hours (range 3.3–4.4 hours). The hepatic cytochrome P450 enzyme CYP2D6 converts hydrocodone into hydromorphone, a more potent opioid (5-fold higher binding affinity to the MOR). However, extensive and poor cytochrome 450 CYP2D6 metabolizers had similar physiological and subjective responses to hydrocodone, and CYP2D6 inhibitor quinidine did not change the responses of extensive metabolizers, suggesting that inhibition of CYP2D6 metabolism of hydrocodone has no practical importance. Ultra-rapid CYP2D6 metabolizers (1–2% of the population) may have an increased response to hydrocodone; however, hydrocodone metabolism in this population has not been studied. Norhydrocodone, the major metabolite of hydrocodone, is predominantly formed by CYP3A4-catalyzed oxidation. In contrast to hydromorphone, it is described as inactive. However, norhydrocodone is actually a MOR agonist with similar potency to hydrocodone, but has been found to produce only minimal analgesia when administered peripherally to animals (likely due to poor blood–brain barrier and thus central nervous system penetration). Inhibition of CYP3A4 in a child who was, in addition, a poor CYP2D6 metabolizer, resulted in a fatal overdose of hydrocodone.
Thus, these algorithms provide a good perspective on the different kinds of algorithms available for protein design. In 2020 scientists reported the development of an AI-based process using genome databases for evolution-based designing of novel proteins. They used deep learning to identify design-rules. In 2022, a study reported deep learning software that can design proteins that contain pre-specified functional sites.
Sources: en.wikipedia.org
They can sedate patients receiving mechanical ventilation or those in extreme distress. Caution is exercised in this situation due to the risk of respiratory depression, and it is recommended that benzodiazepine overdose treatment facilities should be available. They have also been found to increase the likelihood of later PTSD after people have been removed from ventilators. Benzodiazepines are indicated in the management of breathlessness (shortness of breath) in advanced diseases, in particular where other treatments have failed to adequately control symptoms. Benzodiazepines are effective as medication given a couple of hours before surgery to relieve anxiety. They also produce amnesia, which can be useful, as patients may not remember unpleasantness from the procedure. They are also used in patients with dental phobia as well as some ophthalmic procedures like refractive surgery; although such use is controversial and only recommended for those who are very anxious. Midazolam is the most commonly prescribed for this use because of its strong sedative actions and fast recovery time, as well as its water solubility, which reduces pain upon injection. Diazepam and lorazepam are sometimes used. Lorazepam has particularly marked amnesic properties that may make it more effective when amnesia is the desired effect. Benzodiazepines are well known for their strong muscle-relaxing properties and can be useful in the treatment of muscle spasms, although tolerance often develops to their muscle-relaxant effects.
European ancestry being dominant according to all autosomal studies undertaken covering the population, accounting for between 60% and 65% of the average genetic makeup of the Brazilian population. African ancestry among the Brazilians is estimated at 20% to 25% of the average genetic makeup Indigenous ancestry is significant and present in all regions of Brazil, accounting for around 15% to 20% of the average genetic ancestry of Brazilians. From the 19th century, Brazil opened its borders to immigration. About five million people from over 60 countries migrated to Brazil between 1808 and 1972, most of them of Portuguese, Italian, Spanish, German, English, Ukrainian, Polish, Jewish, African, Armenian, Russian, Chinese, Japanese, Korean and Arab origin. Brazil has the second-largest Jewish community in Latin America after Argentina making up 0.06% of its population. Outside of the Arab world, Brazil also has the largest population of Arab ancestry in the world, with 15–20 million people. According to Brazil's Ministry of Foreign Affairs, Brazil is home to a Lebanese diaspora of 7-10 million, surpassing the population of Lebanese individuals residing in Lebanon. Brazilian society is more markedly divided by social class lines, although a high income disparity is found between race groups, so racism and classism often overlap.
== Values for common substances == There are multiple techniques to determine the pKa of a chemical, leading to some discrepancies between different sources. Well measured values are typically within 0.1 units of each other. Data presented here were taken at 25 °C in water. More values can be found in the Thermodynamics section, above. A table of pKa of carbon acids, measured in DMSO, can be found on the page on carbanions.
=== CNO-I === The first proposed catalytic cycle for the conversion of hydrogen into helium was initially called the carbon–nitrogen cycle (CN-cycle), also referred to as the Bethe–Weizsäcker cycle in honor of the independent work of Carl Friedrich von Weizsäcker in 1937–38 and Hans Bethe. Bethe's 1939 papers on the CN-cycle drew on three earlier papers written in collaboration with Robert Bacher and Milton Stanley Livingston and which came to be known informally as Bethe's Bible. It was considered the standard work on nuclear physics for many years and was a significant factor in his being awarded the 1967 Nobel Prize in Physics. Bethe's original calculations suggested the CN-cycle was the Sun's primary source of energy. This conclusion arose from a belief that is now known to be mistaken, that the abundance of nitrogen in the sun is approximately 10%; it is actually less than half a percent. The CN-cycle, named as it contains no stable isotope of oxygen, involves the following cycle of transformations:
=== Ubiquitination and role in development === Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates a number of other proteins and marks them for degradation via the proteasome. Through a mechanism which has not been completely elucidated, this ubiquitination results in reduced levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8 in turn regulates a number of developmental processes, such as limb and auditory vesicle formation. The net result is that this ubiquitin ligase complex is important for limb outgrowth in embryos. At the molecular level, C-terminal cyclic imides have been identified as endogenous degrons recognized by cereblon. Cyclic imides can arise through spontaneous peptide-bond cleavage at asparagine or glutamine residues in aging proteins, and have long been observed in proteins such as α-crystallin. In 2022, C-terminal aspartimide and aminoglutarimide residues were shown to bind the thalidomide-binding domain of cereblon and to function as degrons promoting CRBN-dependent ubiquitination and proteasomal degradation. In the absence of cereblon, DDB1 forms a complex with DDB2 that functions as a DNA damage-binding protein. Furthermore, cereblon and DDB2 bind to DDB1 in a competitive manner.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.